A Multi-Centre Double-Blind Randomised Placebo-Controlled Phase II Study of HDP 99.0006 in Patients with Actinic Keratosis
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Fosfluridine tidoxil (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Therapeutic Use
- Sponsors Heidelberg Pharma Research
- 09 Oct 2017 According to a WILEX AG media release, Heidelberg Pharma changed its name to Heidelberg Pharma Research.
- 12 May 2006 New trial record.